



A Discussion of Long-Term Outcomes of Resynchronization-Defibrillation for Heart Failure

Hosted by William H. Sauer, MD, FHRS, CCDS

Article Information:

Article for Discussion: [Long-Term Outcomes of Resynchronization–Defibrillation for Heart Failure](#)

Authors: John L. Sapp, M.D., Soori Sivakumaran, M.D., Calum J. Redpath, M.B., Ch.B., Ph.D., Habib Khan, M.D., Ratika Parkash, M.D., Derek V. Exner, M.D., Jeff S. Healey, M.D., Bernard Thibault, M.D., Laurence D. Sterns, M.D., Nhat Hung N. Lam, B.Sc., Jaimie Manlucu, M.D., Ahmed Mokhtar, M.D., Glen Sumner, M.D., Stuart McKinlay, B.H.Sc., Shane Kimber, M.D., Blandine Mondesert, M.D., Mario Talajic, M.D., Jean Rouleau, M.D., C. Elizabeth McCarron, Ph.D., George Wells, Ph.D., and Anthony S. L. Tang, M.D., for the RAFT Long-Term Study Team

Publication: New England Journal of Medicine



Today's Host




William H. Sauer, MD, FHRF, CCDS
Brigham and Women's Hospital



Today's Contributors:



Akshay Suvas Desai, MD, MPH
Brigham and Women's Hospital



Sunil Kapur, MD
Brigham and Women's Hospital



Disclosures:

William H. Sauer, MD, FHRS, CCDS

- **Honoraria/Speaking/Consulting:** Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific
- **Research:** Medtronic

Akshay Suvas Desai, MD, MPH

- **Honoraria/Speaking/Consulting:** Abbott, Novartis, AstraZeneca, BioFourmis, Regeneron, Alnylam Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Cytokinetics, AxonTherapies, Avidity Biosciences, Medpace, Merck, New Amsterdam Pharma, Parexel, Roche Diagnostics, GlaxoSmithKline, NovoNordisk, Veristat, Verily/Google, Zydus, River2Renal
- **Research:** Bayer Healthcare Pharmaceuticals, Abbott Medical, AstraZeneca, Novartis

Sunil Kapur, MD

- **Honoraria/Speaking/Consulting:** Medtronic, Novartis, Abbott, Biotronik.





Thank you!